Drug Profile
Terlipressin subcutaneous - NanoAntibiotics /PharmaIN
Alternative Names: PGC-C12E-Terlipressin; PHT 101; SC terlipressin- NanoAntibiotics /PharmaINLatest Information Update: 21 Mar 2023
Price :
$50
*
At a glance
- Originator LAT Pharma; PharmaIN
- Developer BioVie
- Class Antidiuretics; Antihaemorrhagics; Vasoconstrictors; Vasopressins
- Mechanism of Action Vasopressin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Ascites
Most Recent Events
- 21 Mar 2023 Discontinued - Preclinical for Ascites in USA (SC)
- 28 Jul 2018 No recent reports of development identified for preclinical development in Ascites in USA (SC, Controlled release)
- 11 May 2017 BioVie plans a phase II trial for Ascites in USA (NCT03107091)